Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Epilepsy Behav. Consumers spent roughly $31.3 increase in annual sales.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

MMJ Recs

NOVEMBER 17, 2023

The community impact is visible in several key areas: Healthcare Advancements MMJ has expanded the range of treatment options available to patients, offering an alternative to conventional pharmaceuticals. MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). One of the leading cannabis clinicians in the U.S.,

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. –(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. First Patient Expected to be Enrolled by Q2 of 2022. BERWYN, Pa.–(BUSINESS For more information, please visit www.virpaxpharma.com. About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

NORML

AUGUST 26, 2019

There are currently five “pharmaceutical processor” permit holders in Virginia, and they’re about to open for business. These were moms and dads and grandparents of children [with intractable epilepsy] who were using medical cannabis oils. As in, no to anyone who wasn’t an epilepsy patient.].

Marijuana 216

Marijuana Legalization Programs Oil 216

Cannabis Law Report

FEBRUARY 15, 2019

The Singapore Online Citizen reports… Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. These can be administered through pharmaceutical products such as oral solutions and sprays.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Cannabis Law Report

DECEMBER 8, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. The results of this study underscore the safety of our spray film technology.”. “The About Virpax Pharmaceuticals.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

NOVEMBER 10, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. Once the Envelta IND-enabling studies are submitted to the FDA, the data may be cross-referenced to our cancer pain and PTSD INDs.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” . School: University of Maryland.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JUNE 1, 2021

Prior to UroGen, Mr. Barbera held various leadership roles at Dendreon Pharmaceuticals, Allergan, and Medimmune, among others. Sesen Bio remains committed to the health and safety of patients, caregivers and employees. Cautionary Note on Forward-Looking Statements.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. Influencing how information is processed and how nerve cells and synapses in the brain interact, the exact function related to autism is still not well understood, and no pharmaceuticals around yet can ‘fix’ autism.

Treatment 76

Treatment Oil CBD Therapy 76

Puff Puff Post

DECEMBER 2, 2019

The FDA’s Consumer Update reiterated that, with the exception of Epidiolex (a CBD drug for rare forms of epilepsy), the FDA hasn’t approved any other forms of CBD. This is mainly due to a lack of data. One of the reasons for its growth potential is its pharmaceutical application in products such as Epidiolex.

CBD 52

CBD Food Pets Safety 52

Cannabis Law Report

OCTOBER 26, 2019

Sponsors must also ensure compliance with the relevant guidelines as to good clinical practice and safety monitoring and reporting, and ensure that the use of personal information complies with the Privacy Act 1988. The TGA does not evaluate any data relating to the trial. However, the period of extension cannot exceed five years.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

The Cannigma

DECEMBER 22, 2021

Listen & Subscribe: Israel is world-renowned for the research and innovation that is taking place there, and unofficial data suggests that around 20% of the Israeli population uses cannabis. We have autism and epilepsy. It has the – you assume safety, at least to a certain level. EG: The population as well.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

MAY 17, 2019

million increase from 2019 and over double the DEA’s $2.862 billion budget), the FDA is responsible for protecting and promoting public health through controlling and supervising food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, cosmetics, animal foods and feed, and veterinary products.

Food 10

Food DEA Hemp CBD 10